Navigation Links
Scripps Florida scientists develop a process to disrupt hepatitis C virion production
Date:3/21/2008

HCV is a significant human pathogen, infecting more than three percent of the worlds population. The incidence of infection in the United States has been estimated to be as high as 4 million cases. In the March issue of the journal PLoS Pathogens, Timothy Tellinghuisen, an assistant professor in the Department of Infectology at Scripps Florida, and his colleagues describe how they used mutations of the viral NS5A phosphoprotein to disrupt virus particle production at an early stage of assembly. NS5A has long been proposed as a regulator of events in the HCV life cycle, but exactly how it orchestrates these events has been unclear.

The interesting thing about this mutant is that while it triggers totally normal RNA replication, it causes severe defects in the output of infectious virusin fact, it releases no infectious virus that we can detect, says Tellinghuisen. And though this discovery isnt a cure for HCV, it is an important research tool that stops the assembly pathway. Total disruption of the replication process would be a cure for the disease, he adds, and thats the teams long-term goal.

HCV infection is roughly five to seven times more prevalent than HIV, underscoring the pandemic nature of HCV infection. HCV occurs when blood from an infected person enters the body of someone who is not infected. Most new HCV infections are due to illegal drug injections and sharing needles. However, those who had blood transfusions prior to blood donor screening in 1991, healthcare workers who had needle stick accidents, and hemodialysis patients are also at risk for developing HCV infection. The virus predominantly infects the liver, and following many decades of virus reproduction serious disease such as hepatitis (liver inflammation), cirrhosis (liver scarring), and carcinoma (liver cancer) develop. Ultimately, HCV infection destroys the liver, resulting in death. Attempts at curing HCV infections with drug therapy have been only marginally succes
'/>"/>

Contact: Keith McKeown
kmckeown@scrpps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County
3. Scripps research scientists discover chemical triggers for aggression in mice
4. Scripps research scientists find new genetic mutation that halts the development of lupus
5. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
6. Scripps scientists peg wind as the force behind fish booms and busts
7. Scripps research scientists devise approach that stops HIV at earliest stage of infection
8. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
9. Scripps research team wins $4M grant to study effects of chronic marijuana use
10. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...OMX Copenhagen: “EXQ”) announced today...eening Facility (ICCB-L) has been recognized as a ...upports investigators at Harvard Medical School, a...-throughput screening of small molecule and RNAi l...d Copenhagen, Denmark (PRWEB) November 30, 2009 --...
(Date:11/30/2009)...ING, Pa., Nov. 30 The University H...it has signed an agreement with ECRI Institute...medical center members special pricing on ECRI,s l...ent will offer UHC members current data to assist ...t nonprofit organization, is a leader in providing...
(Date:11/30/2009)...ewswire/ -- Raleigh dentist Robert L. Williamson...to educate the community and patients about sedati...a series of free educational videos and online inf...educating the public about the benefits of sedati...al care educational videos are available free onli...
(Date:11/30/2009)...d that beverage can pull-tabs were being swallowed...rers to stay-tabs. But a study presented today at ...North America (RSNA) found that the new tabs are s...actors leading the change in beverage can construc...lowing of the pull-tab and potential related injur...
(Date:11/30/2009)...enient technique that, when added to breast ultras...rom benign results, according to an ongoing study ...logical Society of North America (RSNA). , When ... often use ultrasound to obtain additional informa...ult in more biopsies because of its relatively low...
Breaking Medicine News(10 mins):Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Health News:Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 4Health News:University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services 2Health News:University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services 3Health News:Raleigh Dentist Dr. Robert Williamson to Educate Patients About Sedation Dentistry 2Health News:Beverage can stay-tabs pose swallowing risk 2Health News:Elastography reduces unnecessary breast biopsies 2
...on,t prove cause and effect , , THURSDAY,... enough of the antioxidant vitamins A and C in the...sh researchers say. , The pooled results of 40 stu...se. The average intake among those with asthma was...
...rence Track will Offer Attendees the Latest Resour...el Brands , , NEW YORK, April 16 With consumers ...A audience looking for private label and contract ... 15-17, 2009 at the Jacob K. Javits Convention Cen...
... Ports Calls on Members of Congress to Protect Por...e Safety & Security , , LOS ANGELES and WASHI...clean the air and create good green jobs at our na...denial of the Federal Maritime Commission,s (FMC) ...
...may be applicable to other pathogens , , T...lled SopB enables salmonella bacteria to invade ce...nctions to avoid destruction, Yale University rese...utionary terms, this hijacking of cellular machine...
...Adapts to Dieter,s Lifestyle , , OWINGS MILLS, Md...nnounced the grand opening of its newest Medifast ...ast Weight Control Center is located at The Shops ...9 a.m.-3 p.m. For more information and to find the...
...rsity research team has found that a painful pelvi...requently in adolescent boys. Chronic prostatitis ...genital disease associated with persistent and lif...gative impact that pain, urinary symptoms, and dep...
Other Medicine News:Health News:Low Vitamin A, C Intake Tied to Asthma Risk 2Health News:HBA Global Expo Platforms Private Label/Contract Manufacturing 2Health News:HBA Global Expo Platforms Private Label/Contract Manufacturing 3Health News:Public Health is No. 1, Says U.S. District Judge in Denial of FMC Motion to Shelve the LA-LB Clean Trucks Programs 2Health News:Public Health is No. 1, Says U.S. District Judge in Denial of FMC Motion to Shelve the LA-LB Clean Trucks Programs 3Health News:Public Health is No. 1, Says U.S. District Judge in Denial of FMC Motion to Shelve the LA-LB Clean Trucks Programs 4Health News:Public Health is No. 1, Says U.S. District Judge in Denial of FMC Motion to Shelve the LA-LB Clean Trucks Programs 5Health News:Medifast Weight Control Center Opens in Austin, TX 2Health News:Pelvic pain as prevalent in teens as older males, Queen's researchers discover 2
(Date:11/29/2009)... Stimulated by the ten years of Sy...dical Systems USA announced today, at the Radiolog...g, the formation of its Medical Informatics Divis...w group will integrate all functions associated wi...a platform for future growth. ,, Several organi...
(Date:11/27/2009)...tion to prevent illnesses caused by subtypes A and.... 27 The U.S. Food and ...ple ages 18 years and older to prevent disease cau...Logo: http://www.newscom.com/cgi-bin/prnh/2009082...s Vaccines and Diagnostics in Siena, Italy, was ap...
(Date:11/26/2009)..., South Africa, Nov. 26 The 2009 F...ar Award in the Generic Pharmaceutical Market is p..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...ward, the following criteria were used to benchmar...rs: growth strategy and implementation, degree of ...
Breaking Medicine Technology:FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3FDA Approves Agriflu Seasonal Influenza Vaccine 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4New national adolescent weight control registry will recognize successful teen weight loss efforts 50961 1New national adolescent weight control registry will recognize successful teen weight loss efforts 50961 2New monkey discovered in Brazil 9148 1New monkey discovered in Brazil 9148 2Sustainable bioenergy project has global launch 9145 1Sustainable bioenergy project has global launch 9145 2
...eceived Regulatory Approval for Three Phase II Can...with Chemotherapy --, -- New Clinical Trial Will E... Combination with Carboplatin and Paclitaxe...uticals, Inc. (Nasdaq: PPHM ), a clinical stage b...ibodies for the treatment of cancer and,hepatitis ...
...22 EpiCept Corporation,(Nasdaq and OMX Nordic Exc...ory and clinical status of Ceplene(TM) (histamine ...go: http://www.newscom.com/cgi-bin/prnh/20020513/...arketing Authorization Application,(MAA) seeking m...n has,advanced to the next important step. The Com...
Other Medicine Technology:Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 4EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream 2EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream 3EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream 4
Torso Brief V-85
Female High Waist Brief, Side Closure
Arm Support Sleeves
Short-Sleeve Bolero
Medicine Products: